Form 4: Amicus Therapeutics Officer Sells Shares Under 10b5-1 Plan

Amicus Therapeutics' Chief People Officer, David Michael Clark, sold 25,643 shares of common stock for $11 per share, executed under a pre-arranged 10b5-1 trading plan.

Summary

• David Michael Clark, Chief People Officer of Amicus Therapeutics, Inc. (FOLD), reported a sale of common stock.
• The transaction involved the disposition of 25,643 shares of common stock.
• The shares were sold at a price of $11 per share.
• The transaction date was December 15, 2025.
• Following this transaction, David Michael Clark beneficially owns 271,332 shares of common stock.
• The sale was conducted pursuant to a Rule 10b5-1 trading plan, which was adopted by the reporting person on March 14, 2025.

Sentiment

Score: 5

Explanation: The sentiment is neutral as this is a routine insider transaction executed under a pre-arranged 10b5-1 trading plan, which typically indicates a scheduled liquidity event rather than a reaction to new material information.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding the company's future performance or outlook.

Industry Context

This insider transaction is a routine disclosure for publicly traded companies, reflecting a pre-planned sale by an executive. It does not inherently provide insights into broader industry trends or competitive landscape.

Stakeholder Impact

• Shareholders: The sale represents a minor reduction in insider ownership, but given it's a 10b5-1 plan, it's generally not interpreted as a negative signal regarding the company's prospects.

Key Dates

Keywords

Amicus Therapeutics, FOLD, Insider Trading, Form 4, Stock Sale, 10b5-1 Plan, Chief People Officer, David Michael Clark